文献速递冠心病

Ridaforolimus与Zotarolimus洗脱支架治疗冠心病的随机对照BIONICS试验主要结果

Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).
PubMed 文献 · Circulation · 2017-08-09

BIONICS试验为前瞻性国际1:1随机非劣效性研究,纳入1919例PCI患者,比较新型Ridaforolimus洗脱支架与慢释放Zotarolimus洗脱支架。12个月靶病变失败率两组均为5.4%(单侧95%CI上限1.8%,非劣效P=0.001),支架血栓率低且无差异。

要点

  • 12个月靶病变失败率两组均为5.4%,Ridaforolimus支架非劣效于Zotarolimus支架。
  • 明确/可能支架血栓率Ridaforolimus组0.4% vs Zotarolimus组0.6%(P=0.75)。
  • 13个月支架内晚期管腔丢失0.22±0.41mm vs 0.23±0.39mm(非劣效P=0.004)。

核心结论

  • 在广泛入选标准的患者中,新型Ridaforolimus洗脱支架12个月靶病变失败非劣效于Zotarolimus洗脱支架,且晚期管腔丢失相似。

研究设计与样本

  • 前瞻性、国际、1:1随机非劣效性试验,在76个中心纳入1919例行经皮冠状动脉介入治疗的患者。
  • 允许入选近期心肌梗死、完全闭塞、分叉病变等复杂情况,两组基线临床和造影特征相似。

主要发现

  • 总体平均年龄63.4岁,32.5%患糖尿病,39.7%表现为急性冠脉综合征。
  • 12个月靶病变失败(心源性死亡、靶血管相关心肌梗死和靶病变血运重建复合终点)两组均为5.4%,单侧95%CI上限1.8%,非劣效P=0.001。
  • 明确/可能支架血栓率Ridaforolimus组0.4% vs Zotarolimus组0.6%(P=0.75)。
  • 13个月造影支架内晚期管腔丢失Ridaforolimus组0.22±0.41 mm vs Zotarolimus组0.23±0.39 mm(非劣效P=0.004)。
  • 血管内超声新生内膜增生百分比分别为8.10±5.81和8.85±7.77(非劣效P=0.01)。

关键数值与推荐

  • 非劣效性设计,主要终点为12个月靶病变失败,非劣效界值未在摘要中报告。
  • 13个月晚期管腔丢失非劣效P=0.004;血管内超声新生内膜增生非劣效P=0.01。

临床怎么用

  • Ridaforolimus洗脱支架在代表临床实践的患者中表现出与Zotarolimus洗脱支架相似的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined. METHODS: A prospective, international 1:1 randomized trial was conducted to evaluate in a noninferiority design the relative safety and efficacy of ridaforolimus-eluting stents (RESs) and slow-release zotarolimus-eluting stents among 1919 patients undergoing percutaneous coronary intervention at 76 centers. Inclusion criteria allowed enrollment of patients with recent myocardial infarction, total occlusions, bifurcations lesions, and other complex conditions. RESULTS: Baseline clinical and angiographic characteristics were similar between the groups. Overall, mean age was 63.4 years, 32.5% had diabetes mellitus, and 39.7% presented with acute coronary syndromes. At 12 months, the primary end point of target lesion failure (composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) was 5.4% for both devices (upper bound of 1-sided 95% confidence interval 1.8%, Pnoninferiority=0.001). Definite/probable stent thrombosis rates were low in both groups (0.4% RES versus 0.6% zotarolimus-eluting stent, P=0.75); 13-month angiographic in-stent late lumen loss was 0.22±0.41 mm and 0.23±0.39 mm (Pnoninferiority=0.004) for the RES and zotarolimus-eluting stent groups, respectively, and intravascular ultrasound percent neointimal hyperplasia was 8.10±5.81 and 8.85±7.77, respectively (Pnoninferiority=0.01). CONCLUSIONS: In the present trial, which allowed broad inclusion criteria, the novel RESs met the prespecified criteria for noninferiority compared with zotarolimus-eluting stents for the primary end point of target lesion failure at 12 months and had similar measures of late lumen loss. These findings support the safety and efficacy of RESs in patients who are representative of clinical practice. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01995487.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kandzari DE, Smits PC, Love MP, et al. Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). Circulation. 2017. PMID: 28794001. doi:10.1161/CIRCULATIONAHA.117.028885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。